A significant minority of people presenting with a major depressive episode (MDE) experience co-occurring subsyndromal hypo/manic symptoms. As this presentation may have important prognostic and treatment implications, the DSM-5 codified a new nosological entity, the "mixed features specifier," referring to individuals meeting threshold criteria for an MDE and subthreshold symptoms of (hypo)mania or to individuals with syndromal mania and subthreshold depressive symptoms. The mixed features specifier adds to a growing list of monikers that have been put forward to describe phenotypes characterized by the admixture of depressive and hypomanic symptoms (e.g., mixed depression, depression with mixed features, or depressive mixed states [DMX]). Current treatment guidelines, regulatory approvals, as well the current evidentiary base provide insufficient decision support to practitioners who provide care to individuals presenting with an MDE with mixed features. In addition, all existing psychotropic agents evaluated in mixed patients have largely been confined to patient populations meeting the DSM-IV definition of "mixed states" wherein the co-occurrence of threshold-level mania and threshold-level MDE was required. Toward the aim of assisting clinicians providing care to adults with MDE and mixed features, we have assembled a panel of experts on mood disorders to develop these guidelines on the recognition and treatment of mixed depression, based on the few studies that have focused specifically on DMX as well as decades of cumulated clinical experience.
Introduction
The recent addition of the mixed features specifier in the latest edition of the Diagnostic and Statistical Manual (DSM-5) codifies a new nosological entity characterized by subthreshold hypomanic or manic symptoms occurring during depressive episodes of either major depressive disorder (MDD) or bipolar I or bipolar II disorder. 1 The introduction of the DSM-5 mixed features specifier also reflects a growing consensus that mood disorders may be conceptualized along a spectrum ranging from pure unipolar depression, through an admixture of varying degrees and presentations of depressive and manic symptoms, to pure mania (Figure 1 ). [2] [3] [4] [5] [6] Perhaps one of the greatest challenges in recognizing the existence of mixed depression or depressive mixed states (DMX) is the question of how to optimize treatment for patients with depression who exhibit concomitant subthreshold features of hypomania or mania. Although there are several guidelines available that provide recommendations for the treatment of unipolar depression, for bipolar depression, and for bipolar mania, there is currently only one treatment guideline that has provided decision support for individuals presenting with a major depressive episode with mixed features (i.e., the Florida Best Practice Psychotherapeutic Medication Guidelines for Adults [2015] , available for download at http://www. medicaidmentalhealth.org/_assets/file/Guidelines/Web _2015-Psychotherapeutic%20Medication%20Guidelines %20for%20Adults_Final_Approved1.pdf). [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] In fact, any treatment guidelines developed prior to the release of the DSM-5 that mention "mixed states" are based on the previous DSM-IV diagnostic criteria that refer to co-occurring full-blown, threshold-level depression with full-blown, threshold-level mania (mixed mania) and simply lump mixed states together with bipolar mania in terms of treatment recommendations. 20 Since the release of the DSM-5 in 2013, it has been suggested that clinicians follow existing guidelines written for the treatment of MDD or bipolar disorder (BD) without any particular reference to individuals presenting with depressive episodes with mixed (DMX) features. However, not only is DMX different in its clinical presentation compared to an MDE, it is not pathognomonic of either MDD or BD. Toward the aim of filling the gaps between updated diagnostic criteria, the latest research findings, and optimal clinical practice, we have gathered together a panel of experts on mood disorders to develop a set of guidelines for the recognition and treatment of DMX.
The guideline recommendations throughout this article are made in reference to DSM-5 rather than DSM-IV descriptions and criteria. However, the diagnostic criteria warranting a DSM-5 major depressive episode (MDE) with mixed features diagnosis exclude "overlapping symptoms" of irritability, distractibility, insomnia, and psychomotor agitation as defining of the opposite polarity due to the presence of these symptoms in both mania and depression. The exclusion of overlapping symptoms increases the specificity of the diagnosis at the expense of sensitivity and possibly face validity insofar as most individuals presenting with an MDE and mixed features do present with "overlapping symptoms." [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] The potential of DMX being misdiagnosed and treated as pure unipolar depression is far greater than if unipolar depression is misdiagnosed and mistreated as DMX).
Overview and Key Points
• Not all patients with depression (as part of bipolar disorder or major depressive disorder) should be prescribed an antidepressant.
• All patients who receive antidepressants for an MDE should be monitored for signs of abnormal behavioral activation or psychomotor acceleration.
• The use of antidepressants in MDE patients with mixed features may not alleviate depressive symptoms and may pose a potential hazard for exacerbating subthreshold mania symptoms that accompany depression.
• For an individual presenting with a depressive episode with mixed features, in addition to antidepressant medication, alternative psychotropic agents (e.g., lithium, anticonvulsant mood stabilizers, atypical antipsychotics) with demonstrated efficacy in treating depressive symptoms as part of MDE may be considered.
• You will not know if a depressed patient has (hypo)manic symptoms or a positive family history of bipolar disorder unless you ask! Ask every patient. Every time.
Assessment DSM-5 diagnostic criteria for a major depressive episode 1 (consider an itemized depression screener such as the Quick Inventory Depressive Symptomatology-Self Report or Clinically Useful Depression Outcome Scale) • These alternative diagnostic criteria for DMX also stress how critical it is to assess the patient for any family history of bipolar spectrum disorders: [33] [34] [35] ➢ Always inquire about family history of bipolar symptoms or ANY symptoms of (hypo)mania in patients presenting with a major depressive episode ➢ Inquire about common bipolar comorbidities (e.g., migraine, anxiety disorders, substance abuse, obesity, binge eating, ADHD). Although these comorbidities are observed in both BD and MDD populations, data suggest that patients with BD (especially those with BDII and pediatric populations) are more likely to be affected 17, [36] [37] [38] [39] Differential Diagnosis
• The prognosis for depression with cooccurring subthreshold hypomania (DMX) is much worse than for pure unipolar depression or bipolar depression without mixed features 26, 40 • A significant minority (about 13-20%) of individuals with unipolar DMX will eventually meet diagnostic criteria for bipolar I or bipolar II disorder
• In order to avoid treatments that could worsen symptoms of hypo/mania in MDE patients with mixed features (e.g., antidepressant monotherapy), to prevent the development of resistance to appropriate treatments, and to avert treatment-emergent affective switch (TEAS), it is essential that DMX be distinguished from pure unipolar depression as early as possible [40] [41] [42] [43] [44] [45] • A key differential diagnostic issue is unipolar depression with borderline personality disorder versus DMX. Most of the correlates listed below are also correlates of unipolar depression with borderline personality disorder
• MDD with active substance use disorders could inflate rates of false-positive detection of hypo/mania symptoms and requires a careful longitudinal history 46 • DMX has been associated with:
➢ ʘ Patient self-report assessing current (hypo) manic symptoms
The probabilistic approach to differential diagnosis. Numerous factors, including early age at onset of first depressive episode, seasonality, antidepressant-induced (hypo)mania, and impulsivity, while not diagnostic of bipolar depression, are less common in pure unipolar depression compared to bipolar spectrum disorders. Moreover, the presence of psychotic features and extensive family history of psychopathology are additional probabilistic factors for BD. Patterns of comorbidity can also be evaluated as substance-use disorders, and several medical disorders (e.g., migraine and metabolic disturbances) are more common in BD when compared to MDD. Although the presence of any of these probabilistic qualities is not pathognomic, accumulation of these factors should alert clinicians to the possibility that their patient may lie along the bipolar spectrum, either with mixed depression or with bipolar depression. • Patient self-report that screens for "bipolar spectrum disorder" (which includes bipolar I and bipolar II), and the "probabilistic" approach may help to identify patients who are more likely to have a bipolar spectrum disorder rather than pure unipolar depression ( Figure 2 ) ➢ The same factors that indicate bipolarity are also evident in patients with DMX
• Rule out comorbid conditions that phenotypically overlap with mixed features and/or secondary causes of (hypo)mania, but keep in mind that some secondary causes (e.g., substance use) could be more frequent among individuals with bipolar than unipolar disorder ➢ Drug and/or alcohol misuse 
Treatment
Initial treatment
• Antidepressant monotherapy should probably NOT be utilized for patients with mixed depression of any type (unipolar, BP II, or BP I), given persisting doubts about the relative efficacy of standard antidepressants in treating bipolar disorders and their potential to destabilize mood 7, 8, 11, 12, 25, 32, [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] [67] [68] ➢ It is critical that patients presenting with a major depressive episode be assessed for the presence of any symptoms of (hypo)mania and family history of mood disorder, including bipolar disorder, before initiating treatment ➢ Patients with mixed depression should be monitored regularly for the emergence or worsening of (hypo)mania and suicidality ➢ Tricyclic antidepressants (TCAs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) may carry the highest risk of causing a treatmentemergent affective switch, 11 analyses of mixed mania in BDI (i.e., DMX with severe manic symptoms) ➢ Dose ranges of the atypical antipsychotics suggested in Table 1 may be too strongly sedative for mild to moderate DMX
• No mood stabilizer (lithium and divalproex) is actually approved for use in depression of any kind (unipolar, mixed, bipolar), 86 except lamotrigine, which is approved for maintenance treatment in bipolar I disorder 9, 11, 14, 71 ➢ Lithium has traditionally been considered an effective antidepressant treatment augmentation strategy, and often very low doses of lithium can be effective for selected patients ➢ Lithium is well-known for its anti-suicide, antiaggression, anti-cycling, and antimanic effects. However, lithium also may yield less favorable effects as compared to divalproex in bipolar mixed states. 87 The efficacy of lithium in bipolar depression and especially mixed depression has not been adequately investigated
Patients failing to respond to monotherapy and continuing to experience subthreshold symptoms or relapses
• The treatment of DMX may require a combination of medications 15, 18, 60, 74, 88 ➢ Combinations with potential efficacy in DMX:
ʘ Atypical antipsychotic + mood stabilizer ʘ Atypical antipsychotic + antidepressant ʘ Olanzapine/fluoxetine combination in particular (caution in overweight or obese patients and those with metabolic dysregulation) ʘ Mood stabilizer + antidepressant ➢ If an antidepressant is prescribed for DMX, it should be used in conjunction with a moodstabilizing agent (atypical antipsychotic or mood stabilizer); however, it is questionable whether adding an antidepressant to a mood stabilizer or atypical antipsychotic has therapeutic benefit in bipolar disorder patients 89 ➢ (Hypo)manic symptoms, irritability, dysphoric mood, and insomnia can deteriorate or develop during antidepressant treatment even in conjunction with mood-stabilizing agents 89,90 ➢ The role of antidepressants in long-term treatment is controversial and not established by controlled trials in DMX, but they may be used effectively in a small minority of patients in the long term, 11 particularly if there is a robust initial response or remission without signs of mood destabilization 91 ➢ The combination of olanzapine or risperidone with carbamazepine is not recommended due to potent pharmacokinetic induction of cytochrome P450 enzymes by carbamazepine 15 • The use of additional short-term medication (e.g., benzodiazepines) may be necessary when an acute stressor is imminent or present, early symptoms of relapse (especially insomnia) occur, or anxiety becomes prominent • Transcranial magnetic stimulation (TMS) may also have some efficacy in treating mixed depression; however, this supposition is based on "off-label" data from preliminary trials in bipolar depression; attempt TMS only after other options have been tried 74 Maintenance treatment 11, 17, 71, 74, 106 • In an individual patient, if one of the recommended acute treatments led to prompt remission from the most recent mixed depressive episode, this may be considered evidence in favor of its long-term use as monotherapy
• The preferred strategy is for continuous rather than intermittent treatment with oral medication to prevent new episodes
• Without active acceptance of the need for long-term treatment, adherence may be poor; consider offering enhanced psychological and social support
• Consistent outpatient follow-up is necessary • Long-term treatment is indefinite for the prevention of new episodes and to achieve adequate inter-episode control of residual or chronic mood symptoms
• Because of the high risk of relapse and the apparent progression to more frequent episodes, long-term treatment with appropriate medication is advocated from as early in the illness course as is acceptable to a patient and his or her family
• Remain vigilant to conversion to bipolar disorder of patients whose index episode is diagnosed as unipolar DMX
• In the absence of convincing evidence in favor of longterm treatment with antidepressants, the usual policy should be eventual discontinuation, although a small minority of patients have a robust initial antidepressant response and appear to do well on long-term combination treatment that includes an antidepressant 89
Safety monitoring 56
• Suicide is the main serious safety concern in this population, and an individualized approach is necessary depending on clinical variables, social support, and preexisting suicide risk factors
• Take all possible steps to protect and improve the physical health of patients in your care through active screening and treatment of risk factors or declared disease
• Higher morbidity and mortality have been reported in bipolar patients, even before treatment with psychotropic agents was initiated. It is of growing concern that many of the long-term treatments that appear to be required for mixed depression may add to the burden of physical disease • Mixed depression is especially common in children and adolescents 40, 110 • The risk of antidepressant-induced suicidality may be highest in the pediatric population due to the presence of mixed features 43, 57, 59, 70, 108 ➢ Children and adolescents presenting with major depression should be screened and monitored for any (hypo)manic symptoms, suicidality, and family history of mood disorders ➢ Antidepressant monotherapy should be avoided in children and adolescents until any presence of (hypo)mania or positive family history of bipolar spectrum disorder is ruled out
• With the exception of fluoxetine, the evidence for efficacy of antidepressants in treating major depressive disorder in the pediatric population is not robust 111
• Venlafaxine may have the highest risk of increasing suicidality in children and adolescents 111
Women of child-bearing potential 11, 17, 56 • The postpartum period is a time of very high risk of relapse or recurrence into severe illness in women with mood disorders. Vigilance and close monitoring during the perinatal period is essential, and effective prophylactic treatment should be considered • In pregnancy, there is a risk of teratogenicity from a number of medications used in all phases of treatment. Higher teratogenic risks appear to be associated with certain anticonvulsants (notably, valproate and carbamazepine). Lithium has also been associated with teratogenicity, although prospective studies suggest that the risk is lower than originally described. The lowest risks appear to be associated with the antipsychotics. However, risks for new compounds are usually unknown and always justify caution • Make use of evidence to address poor insight, the seriousness of the illness, reluctance to give up the experience of hypo(mania), the risk of relapse, and the benefit of therapeutic engagement 
